Treatment of Gastric Neuroendocrine Tumors: The Necessity of a Type-Adapted Treatment
The DOI matches its Crossref record.
Abstract
BACKGROUND: Gastric neuroendocrine (or gastric carcinoid) tumors have recently been classified into 3 types that differ in biological behavior and prognosis. Although the necessity of type-adapted treatment is widely accepted, it seems inconsistently used in daily practice. HYPOTHESIS: Diagnostic differentiation into various biological types is necessary for an adequate treatment of gastric neuroendocrine tumors. DESIGN: Retrospective study. SETTING: University hospital department of surgery. PATIENTS: Twenty-seven patients with a histologically verified gastric neuroendocrine tumor. MAIN OUTCOME MEASURES: A univariate analysis of survival rates with respect to tumor type, tumor biological parameters, and treatment performed was accomplished by applying the Kaplan-Meier estimation method. The log-rank test was used to evaluate the level of significance. RESULTS: The 16 type 1 (59%) and 11 type 3 (41%) gastric neuroendocrine tumors differ in tumor size, histopathologic characteristics, and biological behavior. Nine (56%) of 16 type 1 gastric neuroendocrine tumors were treated by local excision, 8 of these (89%) had persistent atrophic gastropathy during the follow-up period. Five-year cumulative survival of patients with type 1 gastric neuroendocrine tumor was 100% without any progression into malignant phenotype. In contrast, 4 (44%) of 9 locally advanced type 3 gastric neuroendocrine tumors were treated radically by extended resection with a 5-year cumulative survival of 75%. CONCLUSIONS: Differentiation into 3 biologically distinct tumor types for gastric neuroendocrine tumors is important with respect to therapeutic strategy and prognostic consideration. Correct diagnosis is attainable by using endoscopy, histopathologic characteristics, and laboratory chemical analysis and should precede any treatment. Extended radical surgery of high-risk type 3 tumors is indicated when definitive healing is achievable, whereas type 1 tumors are best treated by endoscopic removal and long-term follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586
Borch, K., Ahrén, B., Ahlman, H., Falkmer, S., Granérus, G., & Grimelius, L. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000167862.52309.7d · Cited by 287
Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate
Merola, E., Sbrozzi-Vanni, A., Panzuto, F., D’Ambra, G., Di Giulio, E., Pilozzi, E., Capurso, G., Lahner, E., Bordi, C., Annibale, B., et al. (2012) · Neuroendocrinology · doi:10.1159/000329043 · Cited by 132
Defining surgical indications for type I gastric carcinoid tumor
Gladdy, R. A., Strong, V. E., Coit, D., Allen, P. J., Gerdes, H., Shia, J., Klimstra, D. S., Brennan, M. F., & Tang, L. H. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0687-y · Cited by 112
Dacha, S., Razvi, M., Massaad, J., Cai, Q., & Wehbi, M. (2015) · Gastroenterology Report · doi:10.1093/gastro/gov004 · Cited by 97
Metadata
- Authors
- Schindl, M.
- Venue
- Archives of Surgery
- Publisher
- American Medical Association (AMA)
- Published
- 2001-01-01
- Volume
- 136
- Issue
- 1
- Pages
- 49
- ISSN
- 0004-0010 (ISSN-L)
- OpenAlex
- W2143273602
- Cited by
- 89
- References
- 0
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Gastric Neuroendocrine Tumors: The Necessity of a Type-Adapted Treatment. https://app.cochat.ai/papers/10.1001/archsurg.136.1.49
- The paper
- Schindl, M. (2001). Treatment of Gastric Neuroendocrine Tumors: The Necessity of a Type-Adapted Treatment. Archives of Surgery. https://doi.org/10.1001/archsurg.136.1.49
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.